Rhumbline Advisers Praxis Precision Medicines, Inc. Transaction History

Rhumbline Advisers

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	SELL	$0.87 - $1.71 $1,143 - $2,246	-1,314 Reduced 36.51%	2,285 $3,000
Q2 2023 Aug 08, 2023	SELL	$0.83 - $1.18 $49,604 - $70,521	-59,764 Reduced 94.32%	3,599 $4,000
Q1 2023 May 11, 2023	BUY	$0.8 - $4.98 $6,330 - $39,406	7,913 Added 14.27%	63,363 $51,000
Q4 2022 Feb 14, 2023	BUY	$1.88 - $2.49 $494 - $654	263 Added 0.48%	55,450 $132,000
Q3 2022 Nov 10, 2022	BUY	$2.5 - $4.77 $16,807 - $32,068	6,723 Added 13.87%	55,187 $125,000

Q2 2022 Aug 11, 2022	BUY	$1.75 - $11.34 $12,404 - $80,377	7,088 Added 17.13%	48,464 $119,000
Q1 2022 May 12, 2022	BUY	$10.21 - $20.29 $35,398 - $70,345	3,467 Added 9.15%	41,376 $422,000
Q4 2021 Feb 10, 2022	BUY	$16.76 - $22.99 $38,061 - $52,210	2,271 Added 6.37%	37,909 $747,000
Q3 2021 Nov 12, 2021	BUY	$13.15 - $22.56 $86,369 - $148,174	6,568 Added 22.59%	35,638 $659,000
Q2 2021 Aug 05, 2021	BUY	$18.28 - $33.05 $337,832 - $610,797	18,481 Added 174.53%	29,070 $531,000
Q1 2021 May 06, 2021	BUY	$29.34 - $60.2 $14,787 - $30,340	504 Added 5.0%	10,589 $347,000
Q4 2020 Feb 10, 2021	BUY	$27.25 - $55.82 $274,816 - $562,944	10,085 New	10,085 $555,000

75K

Ticker PRAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,576,100
Market Cap $1.84B
Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of ...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.